A Phase I Study of Intratumoral/Peritumoral Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory or Recurrent High Grade Gliomas (HGG)

Trial Profile

A Phase I Study of Intratumoral/Peritumoral Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory or Recurrent High Grade Gliomas (HGG)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs HSV 1716 (Primary) ; Dexamethasone
  • Indications Glioma
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 07 Jun 2016 Last checked against the ClinicalTrials.gov record.
    • 26 May 2016 Status changed from recruiting to discontinued.
    • 14 Jan 2014 New source identified and integrated ( ClinicalTrials.gov, NCT02031965)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top